Literature DB >> 7991613

Beta-amyloid neurotoxicity requires fibril formation and is inhibited by congo red.

A Lorenzo1, B A Yankner.   

Abstract

beta-Amyloid (beta A) is normally produced as a nontoxic soluble peptide. In Alzheimer disease, beta A aggregates and accumulates in the brain as inert diffuse plaques or compact plaques associated with neurodegenerative changes. To determine the relationship of neurotoxicity to the physical state of beta A, we created (i) nonamyloidogenic amorphous aggregates of beta A [amorphous beta A (Am-beta A)] analogous to diffuse plaques and (ii) amyloidogenic fibrils of beta A [fibrillar beta A (Fib-beta A)] analogous to compact plaques. In primary rat hippocampal culture, Fib-beta A was neurotoxic, whereas Am-beta A was not toxic. Fib-beta A caused significant loss of synapses in viable neurons, while Am-beta A had no effect on synapse number. The amyloid fibril-binding dye Congo red inhibited Fib-beta A neurotoxicity by inhibiting fibril formation or by binding to preformed fibrils. Congo red also inhibited the pancreatic islet cell toxicity of diabetes-associated amylin, another type of amyloid fibril. These results indicate that beta A neurotoxicity requires fibril formation. These findings and our previous demonstration that amylin fibrils are toxic suggest that a common cytopathic effect of amyloid fibrils may contribute to the pathogenesis of Alzheimer disease and other amyloidoses.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7991613      PMCID: PMC45413          DOI: 10.1073/pnas.91.25.12243

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  31 in total

1.  Neurotrophic and neurotoxic effects of amyloid beta protein: reversal by tachykinin neuropeptides.

Authors:  B A Yankner; L K Duffy; D A Kirschner
Journal:  Science       Date:  1990-10-12       Impact factor: 47.728

Review 2.  Seminars in medicine of the Beth Israel Hospital, Boston. beta-Amyloid and the pathogenesis of Alzheimer's disease.

Authors:  B A Yankner; M M Mesulam
Journal:  N Engl J Med       Date:  1991-12-26       Impact factor: 91.245

3.  Alzheimer patients and Down patients: cerebral preamyloid deposits differ ultrastructurally and histochemically from the amyloid of senile plaques.

Authors:  L Verga; B Frangione; F Tagliavini; G Giaccone; A Migheli; O Bugiani
Journal:  Neurosci Lett       Date:  1989-11-06       Impact factor: 3.046

4.  The precursor of Alzheimer's disease amyloid A4 protein resembles a cell-surface receptor.

Authors:  J Kang; H G Lemaire; A Unterbeck; J M Salbaum; C L Masters; K H Grzeschik; G Multhaup; K Beyreuther; B Müller-Hill
Journal:  Nature       Date:  1987 Feb 19-25       Impact factor: 49.962

5.  Alzheimer's disease: initial report of the purification and characterization of a novel cerebrovascular amyloid protein.

Authors:  G G Glenner; C W Wong
Journal:  Biochem Biophys Res Commun       Date:  1984-05-16       Impact factor: 3.575

6.  An in vivo model for the neurodegenerative effects of beta amyloid and protection by substance P.

Authors:  N W Kowall; M F Beal; J Busciglio; L K Duffy; B A Yankner
Journal:  Proc Natl Acad Sci U S A       Date:  1991-08-15       Impact factor: 11.205

7.  Effects of injected Alzheimer beta-amyloid cores in rat brain.

Authors:  S A Frautschy; A Baird; G M Cole
Journal:  Proc Natl Acad Sci U S A       Date:  1991-10-01       Impact factor: 11.205

8.  Ultrastructure of diffuse plaques in senile dementia of the Alzheimer type: comparison with primitive plaques.

Authors:  H Yamaguchi; Y Nakazato; M Shoji; M Takatama; S Hirai
Journal:  Acta Neuropathol       Date:  1991       Impact factor: 17.088

Review 9.  Methodological variables in the assessment of beta amyloid neurotoxicity.

Authors:  J Busciglio; A Lorenzo; B A Yankner
Journal:  Neurobiol Aging       Date:  1992 Sep-Oct       Impact factor: 4.673

10.  Beta-amyloid from Alzheimer disease brains inhibits sprouting and survival of sympathetic neurons.

Authors:  A E Roher; M J Ball; S V Bhave; A R Wakade
Journal:  Biochem Biophys Res Commun       Date:  1991-01-31       Impact factor: 3.575

View more
  234 in total

1.  beta -Amyloid peptide blocks the response of alpha 7-containing nicotinic receptors on hippocampal neurons.

Authors:  Q Liu ; H Kawai; D K Berg
Journal:  Proc Natl Acad Sci U S A       Date:  2001-03-27       Impact factor: 11.205

2.  Amyloid-beta peptide assembly: a critical step in fibrillogenesis and membrane disruption.

Authors:  C M Yip; J McLaurin
Journal:  Biophys J       Date:  2001-03       Impact factor: 4.033

3.  Repetitive mild brain trauma accelerates Abeta deposition, lipid peroxidation, and cognitive impairment in a transgenic mouse model of Alzheimer amyloidosis.

Authors:  Kunihiro Uryu; Helmut Laurer; Tracy McIntosh; Domenico Praticò; Daniel Martinez; Susan Leight; Virginia M-Y Lee; John Q Trojanowski
Journal:  J Neurosci       Date:  2002-01-15       Impact factor: 6.167

4.  An atomic model for the pleated beta-sheet structure of Abeta amyloid protofilaments.

Authors:  L Li; T A Darden; L Bartolotti; D Kominos; L G Pedersen
Journal:  Biophys J       Date:  1999-06       Impact factor: 4.033

5.  A cell surface receptor complex for fibrillar beta-amyloid mediates microglial activation.

Authors:  Maria E Bamberger; Meera E Harris; Douglas R McDonald; Jens Husemann; Gary E Landreth
Journal:  J Neurosci       Date:  2003-04-01       Impact factor: 6.167

6.  Preparation and characterization of toxic Abeta aggregates for structural and functional studies in Alzheimer's disease research.

Authors:  Asad Jan; Dean M Hartley; Hilal A Lashuel
Journal:  Nat Protoc       Date:  2010-06-03       Impact factor: 13.491

7.  Charge-based binding of complement component C1q to the Alzheimer amyloid beta-peptide.

Authors:  S Webster; B Bonnell; J Rogers
Journal:  Am J Pathol       Date:  1997-05       Impact factor: 4.307

8.  Expression and purification of amyloid-beta peptides from Escherichia coli.

Authors:  Kanchan Garai; Scott L Crick; Sourajit M Mustafi; Carl Frieden
Journal:  Protein Expr Purif       Date:  2009-02-20       Impact factor: 1.650

Review 9.  Amyloid beta-protein assembly as a therapeutic target of Alzheimer's disease.

Authors:  Ghiam Yamin; Kenjiro Ono; Mohammed Inayathullah; David B Teplow
Journal:  Curr Pharm Des       Date:  2008       Impact factor: 3.116

10.  Amyloid beta peptide potentiates cytokine secretion by interleukin-1 beta-activated human astrocytoma cells.

Authors:  B D Gitter; L M Cox; R E Rydel; P C May
Journal:  Proc Natl Acad Sci U S A       Date:  1995-11-07       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.